眼内炎与玻璃体腔内注射相关：门诊环境与手术室环境。

Endophthalmitis associated with intravitreal injections: office-based setting and operating room setting.

机构信息

*Retina-Vitreous Associates Medical Group, Los Angeles, California; †Department of Ophthalmology, University of Bari, Bari, Italy; ‡Department of Ophthalmology, Polytechnic University of Ancona, Ancona, Italy; and §Bascom Palmer Eye Institute, Miami, Florida.

出版信息

Retina. 2014 Jan;34(1):18-23. doi: 10.1097/IAE.0000000000000008.

DOI:10.1097/IAE.0000000000000008

PMID:24362413

Abstract

PURPOSE

To report on the occurrence of endophthalmitis after intravitreal injections (IVI) in two different settings: office-based and operating room.

METHODS

Consecutive case series. Retrospective review of all patients who underwent IVI by 2 physicians between January 2009 and December 2011. Group A underwent IVI in the examination room in office-based setting and Group B underwent IVI in the operating room.

RESULTS

A total of 11,710 IVIs were performed during the study period. Group A: A total of 8,647 IVIs performed including 2,041 ranibizumab, 6,169 bevacizumab, and 437 triamcinolone acetonide. The diagnosis included neovascular age-related macular degeneration (5,376), diabetic macular edema (1,587), retinal vein occlusion (1,068), and miscellaneous diagnosis (616). Group B: A total of 3,063 IVIs performed including 683 ranibizumab, 2,364 bevacizumab, and 16 triamcinolone acetonide. The diagnosis included neovascular age-related macular degeneration (1,836), diabetic macular edema (771), retinal vein occlusion (189), and miscellaneous diagnosis (267). A total of 5 cases (0.043%) of clinically suspected endophthalmitis occurred in 11,710 injections. Three cases (0.035%) occurred in Group A, and 2 cases (0.065%) occurred in Group B.

CONCLUSION

The rate of clinically suspected endophthalmitis after IVIs is low whether the procedure is performed in the office or operating room setting. The findings have implications in terms of the patient convenience, efficiency, and cost of administrating these treatments.

摘要

目的

报告两种不同环境下（诊室和手术室）玻璃体腔内注射（IVI）后发生眼内炎的情况。

方法

连续病例系列研究。回顾 2009 年 1 月至 2011 年 12 月期间由 2 位医生进行的所有 IVI 患者。A 组在诊室的检查室内进行 IVI，B 组在手术室进行 IVI。

结果

研究期间共进行了 11710 次 IVI。A 组：共进行了 8647 次 IVI，其中包括 2041 次雷珠单抗、6169 次贝伐单抗和 437 次曲安奈德。诊断包括新生血管性年龄相关性黄斑变性（5376 例）、糖尿病性黄斑水肿（1587 例）、视网膜静脉阻塞（1068 例）和其他诊断（616 例）。B 组：共进行了 3063 次 IVI，其中包括 683 次雷珠单抗、2364 次贝伐单抗和 16 次曲安奈德。诊断包括新生血管性年龄相关性黄斑变性（1836 例）、糖尿病性黄斑水肿（771 例）、视网膜静脉阻塞（189 例）和其他诊断（267 例）。在 11710 次注射中，共发生 5 例（0.043%）临床疑似眼内炎。A 组发生 3 例（0.035%），B 组发生 2 例（0.065%）。